Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial

Aggarwal C, Martinez-Marti A, Majem M, et al. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2518440. doi:10.1001/jamanetworkopen.2025.18440. | PMID: N/A

This study updates the COAST randomized clinical trial investigating the efficacy and safety of durvalumab alone or in combination with novel agents in patients with unresectable stage III non-small cell lung cancer following chemoradiotherapy.

Key Learning Points

• •
  Durvalumab combined with novel agents shows improved efficacy over durvalumab alone in unresectable stage III NSCLC.
• •
  The safety profile of combined therapies remains manageable with ongoing monitoring required.